NCT03564977

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

CD19-targeted CAR-T Cell Therapy for Minimal Residual Disease in B-cell Malignancies After Autologous Stem Cell Transplantation

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Qingdao Central Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to explore the efficacy of CD19-targeted CAR-T cell therapy for minimal residual disease (MRD) in B-cell Malignancies after autologous stem cell transplantation.

Detailed description

Relapse is a common cause of failure in patients with B-cell malignancies after autologous stem cell transplantation. CD19-targeted CAR-T cells showed excellent therapeutic efficiency in B-cell malignancies. Investigators attempt to treat minimal residual disease (MRD)-positive B-cell Malignancies after autologous stem cell transplantation by CD19-targeted CAR-T cells and hope to explore the therapeutic effects of CD19-targeted CAR-T cell therapy.

Conditions

• Lymphoma, B-Cell
• Leukemia, B-Cell
• Minimal Disease, Residual

Interventions

Type	Name	Description
BIOLOGICAL	CD19-targeted CAR-T cells	MDR+ patients after autologous stem cell transplantation were treated with CD19-targeted CAR-T cells.

Timeline

• Start date: 2018-07-15
• Primary completion: 2020-06-15
• Completion: 2020-06-15
• First posted: 2018-06-21
• Last updated: 2018-07-02

Locations

1 site across 1 country: China